Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 109

1.

Authors' Reply.

Ring L, Abu-Omar Y, Kaye N, Rana BS, Watson W, Dutka DP, Vassiliou VS.

J Am Soc Echocardiogr. 2019 Apr;32(4):545-547. doi: 10.1016/j.echo.2019.01.021. No abstract available.

PMID:
30954123
2.

Left Atrial Function Is Associated with Earlier Need for Cardiac Surgery in Moderate to Severe Mitral Regurgitation: Usefulness in Targeting for Early Surgery.

Ring L, Abu-Omar Y, Kaye N, Rana BS, Watson W, Dutka DP, Vassiliou VS.

J Am Soc Echocardiogr. 2018 Sep;31(9):983-991. doi: 10.1016/j.echo.2018.03.011. Epub 2018 May 24.

PMID:
29804897
3.

The Normal Mitral Valve Annulus in Humans Defined Using 3-Dimensional Transesophageal Echocardiography.

Ring L, Dutka DP, Boyd J, Parker K, Wendler O, Monaghan MJ, Rana BS.

JACC Cardiovasc Imaging. 2018 Mar;11(3):510-512. doi: 10.1016/j.jcmg.2017.05.017. Epub 2017 Aug 16. No abstract available.

4.

Glucagon-like peptide-1 derived cardioprotection does not utilize a KATP-channel dependent pathway: mechanistic insights from human supply and demand ischemia studies.

Giblett JP, Axell RG, White PA, Clarke SJ, McCormick L, Read PA, Reinhold J, Brown AJ, O'Sullivan M, West NE, Dutka DP, Hoole SP.

Cardiovasc Diabetol. 2016 Jul 19;15:99. doi: 10.1186/s12933-016-0416-3.

5.

Glucagon-Like Peptide-1: A Promising Agent for Cardioprotection During Myocardial Ischemia.

Giblett JP, Clarke SJ, Dutka DP, Hoole SP.

JACC Basic Transl Sci. 2016 Jun 27;1(4):267-276. doi: 10.1016/j.jacbts.2016.03.011. eCollection 2016 Jun. Review.

6.

9th Hatter Biannual Meeting: position document on ischaemia/reperfusion injury, conditioning and the ten commandments of cardioprotection.

Bell RM, Bøtker HE, Carr RD, Davidson SM, Downey JM, Dutka DP, Heusch G, Ibanez B, Macallister R, Stoppe C, Ovize M, Redington A, Walker JM, Yellon DM.

Basic Res Cardiol. 2016 Jul;111(4):41. doi: 10.1007/s00395-016-0558-1. Epub 2016 May 10. Review.

7.
8.

Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus.

McCormick LM, Heck PM, Ring LS, Kydd AC, Clarke SJ, Hoole SP, Dutka DP.

Cardiovasc Diabetol. 2015 Aug 8;14:102. doi: 10.1186/s12933-015-0259-3.

9.

Pre-treatment with glucagon-like Peptide-1 protects against ischemic left ventricular dysfunction and stunning without a detected difference in myocardial substrate utilization.

McCormick LM, Hoole SP, White PA, Read PA, Axell RG, Clarke SJ, O'Sullivan M, West NEJ, Dutka DP.

JACC Cardiovasc Interv. 2015 Feb;8(2):292-301. doi: 10.1016/j.jcin.2014.09.014.

10.

Remote ischemic conditioning: from experimental observation to clinical application: report from the 8th Biennial Hatter Cardiovascular Institute Workshop.

Pickard JM, Bøtker HE, Crimi G, Davidson B, Davidson SM, Dutka D, Ferdinandy P, Ganske R, Garcia-Dorado D, Giricz Z, Gourine AV, Heusch G, Kharbanda R, Kleinbongard P, MacAllister R, McIntyre C, Meybohm P, Prunier F, Redington A, Robertson NJ, Suleiman MS, Vanezis A, Walsh S, Yellon DM, Hausenloy DJ.

Basic Res Cardiol. 2015 Jan;110(1):453. doi: 10.1007/s00395-014-0453-6. Epub 2014 Dec 2. Review.

11.

Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.

Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Bělohlávek J, Böhm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, Gonzàlez-Medina A, Hagège AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan Ö, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC; PARADIGM-HF Investigators and Coordinators.

Circulation. 2015 Jan 6;131(1):54-61. doi: 10.1161/CIRCULATIONAHA.114.013748. Epub 2014 Nov 17.

PMID:
25403646
12.

Development of a multiparametric score to predict left ventricular remodelling and prognosis after cardiac resynchronization therapy.

Kydd AC, Khan FZ, Ring L, Pugh PJ, Virdee MS, Dutka DP.

Eur J Heart Fail. 2014 Nov;16(11):1206-13. doi: 10.1002/ejhf.167. Epub 2014 Oct 10.

13.

Angiotensin-neprilysin inhibition versus enalapril in heart failure.

McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees.

N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30.

14.
15.

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.

Lincoff AM, Tardif JC, Schwartz GG, Nicholls SJ, Rydén L, Neal B, Malmberg K, Wedel H, Buse JB, Henry RR, Weichert A, Cannata R, Svensson A, Volz D, Grobbee DE; AleCardio Investigators.

JAMA. 2014 Apr 16;311(15):1515-25. doi: 10.1001/jama.2014.3321.

PMID:
24682069
16.

Darapladib for preventing ischemic events in stable coronary heart disease.

STABILITY Investigators, White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, Budaj A, Harrington RA, Steg PG, Ardissino D, Armstrong PW, Avezum A, Aylward PE, Bryce A, Chen H, Chen MF, Corbalan R, Dalby AJ, Danchin N, De Winter RJ, Denchev S, Diaz R, Elisaf M, Flather MD, Goudev AR, Granger CB, Grinfeld L, Hochman JS, Husted S, Kim HS, Koenig W, Linhart A, Lonn E, López-Sendón J, Manolis AJ, Mohler ER 3rd, Nicolau JC, Pais P, Parkhomenko A, Pedersen TR, Pella D, Ramos-Corrales MA, Ruda M, Sereg M, Siddique S, Sinnaeve P, Smith P, Sritara P, Swart HP, Sy RG, Teramoto T, Tse HF, Watson D, Weaver WD, Weiss R, Viigimaa M, Vinereanu D, Zhu J, Cannon CP, Wallentin L.

N Engl J Med. 2014 May 1;370(18):1702-11. doi: 10.1056/NEJMoa1315878. Epub 2014 Mar 30.

17.

Atrial function as a guide to timing of intervention in mitral valve prolapse with mitral regurgitation.

Ring L, Rana BS, Wells FC, Kydd AC, Dutka DP.

JACC Cardiovasc Imaging. 2014 Mar;7(3):225-32. doi: 10.1016/j.jcmg.2013.12.009. Epub 2014 Feb 13.

18.

Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.

McCormick LM, Kydd AC, Read PA, Ring LS, Bond SJ, Hoole SP, Dutka DP.

Circ Cardiovasc Imaging. 2014 Mar;7(2):274-81. doi: 10.1161/CIRCIMAGING.113.000785. Epub 2014 Feb 6.

PMID:
24503784
19.

Optimising cardioprotection during myocardial ischaemia: targeting potential intracellular pathways with glucagon-like peptide-1.

Clarke SJ, McCormick LM, Dutka DP.

Cardiovasc Diabetol. 2014 Jan 11;13:12. doi: 10.1186/1475-2840-13-12. Review.

20.

Utility of speckle tracking echocardiography to characterize dysfunctional myocardium in patients with ischemic cardiomyopathy referred for cardiac resynchronization therapy.

Kydd AC, Khan F, Gopalan D, Ring L, Rana BS, Virdee MS, Dutka DP.

Echocardiography. 2014 Jul;31(6):736-43. doi: 10.1111/echo.12458. Epub 2013 Dec 5.

PMID:
24303794

Supplemental Content

Loading ...
Support Center